01/27/23 8:30 AMNasdaq : SLRX clinical triallow floatSalarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitPreclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance than standard-of-care treatment Company plans to submit an Investigational New Drug application to the U.S. Food and DrugRHEA-AIneutral
01/19/23 8:30 AMNasdaq : SLRX conferencesclinical triallow floatSalarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development SummitSalariusRHEA-AIneutral
01/05/23 8:00 AMNasdaq : SLRX low floatSalarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein DegradersSalariusRHEA-AIneutral
12/13/22 8:01 AMNasdaq : SLRX clinical triallow floatInvestigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual MeetingPatients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who relapsed or progressed after hypomethylating agentRHEA-AInegative
12/13/22 8:00 AMNasdaq : SLRX low floatSalarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual MeetingSignificant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid ®) Synergistic activity with rituximab in DLBCL mouse model resulted in complete regressions and was superior to the approved regimen, lenalidomideRHEA-AIneutral
12/08/22 8:00 AMNasdaq : SLRX clinical triallow floatSalarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASHSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients inRHEA-AIneutral
12/01/22 8:00 AMNasdaq : SLRX clinical triallow floatSalarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas RHEA-AIneutral
11/10/22 8:30 AMNasdaq : SLRX earningslow floatSalarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for theRHEA-AIneutral
11/03/22 9:57 AMNasdaq : SLRX low floatSalarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual MeetingSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstractsRHEA-AIneutral
10/27/22 8:30 AMNasdaq : SLRX clinical triallow floatSalarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation ConferenceSalariusRHEA-AIneutral